Ross C. Klingsberg

2.0k total citations
9 papers, 438 citations indexed

About

Ross C. Klingsberg is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ross C. Klingsberg has authored 9 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Ross C. Klingsberg's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Pediatric health and respiratory diseases (2 papers) and Peptidase Inhibition and Analysis (2 papers). Ross C. Klingsberg is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Pediatric health and respiratory diseases (2 papers) and Peptidase Inhibition and Analysis (2 papers). Ross C. Klingsberg collaborates with scholars based in United States, France and Germany. Ross C. Klingsberg's co-authors include Joseph A. Lasky, Bin Shan, Weichao Guo, Michael L. Palmer, Hong T. Nguyen, Tso‐Pang Yao, Hui Tao, Ying Zhuo, Steven E. Mutsaers and Nguyễn Thị Hồng and has published in prestigious journals such as Journal of Biological Chemistry, CHEST Journal and Frontiers in Microbiology.

In The Last Decade

Ross C. Klingsberg

8 papers receiving 433 citations

Peers

Countries citing papers authored by Ross C. Klingsberg

Since Specialization

Citations

This map shows the geographic impact of Ross C. Klingsberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross C. Klingsberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross C. Klingsberg more than expected).

Fields of papers citing papers by Ross C. Klingsberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross C. Klingsberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross C. Klingsberg. The network helps show where Ross C. Klingsberg may publish in the future.

Co-authorship network of co-authors of Ross C. Klingsberg

This figure shows the co-authorship network connecting the top 25 collaborators of Ross C. Klingsberg. A scholar is included among the top collaborators of Ross C. Klingsberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross C. Klingsberg. Ross C. Klingsberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	A RAPIDLY PROGRESSIVE CASE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS AFTER COVID-19 INFECTION 2024 ·CHEST Journal ·(unknown), (unknown), Ross C. Klingsberg	0
2	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events 2020 ·Journal of Cystic Fibrosis ·C. Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, Ross C. Klingsberg, Rainald Fischer, Steven M. Rowe, Paul Audhya, Neil Ahluwalia, Xiaojun You, Thomas J. Ferro, Margaret E. Duncan, Bote G. Bruinsma	18
3	Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study 2019 ·Pneumologie ·C. Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, Ross C. Klingsberg, R. Fischer, (unknown), Paul Audhya, (unknown), Xiaojun You, Thomas J. Ferro	3
4	Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis? 2018 ·Frontiers in Microbiology ·Christopher Vinnard, Alyssa Mezochow, (unknown), Ross C. Klingsberg, John Hansen‐Flaschen, Keith Hamilton	9
5	A 45-Year-Old Woman With 3 Weeks of Cough and Night Sweats 2016 ·CHEST Journal ·(unknown), (unknown), Ross C. Klingsberg	1
6	The Epstein-Barr Virus Latent Membrane Protein 1 and Transforming Growth Factor–β1 Synergistically Induce Epithelial–Mesenchymal Transition in Lung Epithelial Cells 2010 ·American Journal of Respiratory Cell and Molecular Biology ·(unknown), Ross C. Klingsberg, Bin Shan, (unknown), Nguyễn Thị Hồng, (unknown), Takashi Takahashi, Erik K. Flemington, Joseph A. Lasky	50
7	Current clinical trials for the treatment of idiopathic pulmonary fibrosis 2009 ·Respirology ·Ross C. Klingsberg, Steven E. Mutsaers, Joseph A. Lasky	20
8	Abrogation of TGF-β1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition 2009 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Weichao Guo, Bin Shan, Ross C. Klingsberg, (unknown), Joseph A. Lasky	188
9	Requirement of HDAC6 for Transforming Growth Factor-β1-induced Epithelial-Mesenchymal Transition 2008 ·Journal of Biological Chemistry ·Bin Shan, Tso‐Pang Yao, Hong T. Nguyen, Ying Zhuo, (unknown), Ross C. Klingsberg, Hui Tao, Michael L. Palmer, (unknown), Joseph A. Lasky	149

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact